Company intelligence / Profile preview
Synsorb Biotech
Calgary, Alberta, Canada
- Ownership
- Private
- Development stage
- Other
01
Overview
Synsorb developed oral carbohydrate-based drugs designed to bind and neutralize bacterial toxins rather than kill bacteria directly. Its lead product, Synsorb Pk, was in Phase III trials for prevention of hemolytic uremic syndrome due to verotoxigenic E. coli infection; another product, Synsorb Cd, was in Phase II trials for recurrent Clostridium difficile-associated diarrhea as of the late 1990s/early 2000s. The company also explored cancer therapeutics using reovirus targeting the Ras pathway after acquiring Oncolytics Biotech Inc.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Synthetic carbohydrateSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Ocean Pharmaceuticals Inc. (antibiotics from marine microorganisms)GeneSense Technologies Inc. (antisense technology targeting cancer)
Beyond the preview
Go deeper on Synsorb Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synsorb Biotech.